Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BLS PharmaceuticalsFRA:PR80 +6.68%37 EV-to-FCF is 873.68 as of Jul. 14, 2026, which is 281732% above its 10-year median of 0.31. GuruFocus rates FRA:PR80 with a GF Score™ of 37/100 and a GF Value™ of €0.41 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 335 Biotechnology companies, BLS Pharmaceuticals ranks worse than 98.21% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BLS Pharmaceuticals's Enterprise Value is €133.67 Mil.
BLS Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.15 Mil. Therefore, BLS Pharmaceuticals's EV-to-FCF for today is 873.68.
The historical rank and industry rank for BLS Pharmaceuticals's EV-to-FCF or its related term are showing as below:
FRA:PR80'
s EV-to-FCF Range Over the Past 10 Years
Min: -56.59 Med: 0.31 Max: 1010.93
Current: 780.36
During the past 13 years, the highest EV-to-FCF of BLS Pharmaceuticals was 1010.93. The lowest was -56.59. And the median was 0.31.
FRA:PR80's EV-to-FCF is ranked worse than 98.21% of 335
companies
in the Biotechnology industry
Industry Median: 15.34
vs FRA:PR80: 780.36
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BLS Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
BLS Pharmaceuticals's share price for today is €0.5781.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BLS Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.021.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BLS Pharmaceuticals EV-to-FCF Related Terms
BLS Pharmaceuticals EV-to-FCF Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BLS Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BLS Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BLS Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where BLS Pharmaceuticals's EV-to-FCF falls into.
BLS Pharmaceuticals's current Enterprise Value is €133.67 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BLS Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.15 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals (FRA:PR80) has a EV-to-FCF of 873.68 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BLS Pharmaceuticals and its competitors. This is 281732% above median its historical median of 0.31. According to the industry distribution chart, BLS Pharmaceuticals ranks #329 out of 335 companies in the Biotechnology industry, placing it in the top 98.2%.
Is BLS Pharmaceuticals' EV-to-FCF too high?
BLS Pharmaceuticals' current EV-to-FCF of 873.68 is 281732% above median its 10-year median of 0.31. The Biotechnology industry median EV-to-FCF is 15.34. BLS Pharmaceuticals' value of 873.68 is 5595.4% above this industry median. Based on the distribution chart, BLS Pharmaceuticals ranks #329 out of 335 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BLS Pharmaceuticals has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' EV-to-FCF compare to ?
According to the Biotechnology industry distribution chart, BLS Pharmaceuticals ranks #329 out of 335 companies for EV-to-FCF. This places BLS Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 15.34. BLS Pharmaceuticals' value of 873.68 is 5595.4% above this benchmark. While the company's 10-year median is 0.31 vs. the industry median of 15.34, BLS Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.34, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BLS Pharmaceuticals's current EV-to-FCF of 873.68 is 5595.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on BLS Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BLS Pharmaceuticals's current EV-to-FCF is 873.68, which is 281732% above median its own 10-year median of 0.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (FRA:PR80) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.41, compared to a current price of €0.58 — trading 41% above its estimated fair value. The current EV-to-FCF is 873.68, which is 281732% above median its 10-year median of 0.31 and 5595.4% above the Biotechnology industry median of 15.34. BLS Pharmaceuticals' overall GF Score™ is 37/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For BLS Pharmaceuticals (FRA:PR80), the current EV-to-FCF is 873.68 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (FRA:PR80) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of €0.58 is trading 41% above its estimated GF Value™ of €0.41.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:PR80:
EV-to-FCF: 873.68 (281732% above median its 10-year median of 0.31)
GF Value™: €0.41 vs. price of €0.58 (41% above fair value)
Industry Position: 5595.4% above the Biotechnology median (#329 of 335)
No single metric tells the full story. See the FRA:PR80 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
37GF Score
Get the complete analysis for FRA:PR80
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PR80 has been successfully added to your 
